Cargando…
De-escalation in breast cancer surgery
In recent years, several trials of breast cancer treatment have failed to demonstrate a survival benefit for some previously routine surgical therapies in selected patient groups. As each of these therapeutic approaches has been deemed of low value deimplementation has varied significantly. This dem...
Autores principales: | Shubeck, Sarah P., Morrow, Monica, Dossett, Lesly A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866473/ https://www.ncbi.nlm.nih.gov/pubmed/35197478 http://dx.doi.org/10.1038/s41523-022-00383-4 |
Ejemplares similares
-
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019) -
Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: in defense of de-escalation
por: Lake, Diana, et al.
Publicado: (2019) -
De-escalation yes, but not at the expense of efficacy: in defense of better treatment
por: Shapiro, Charles L.
Publicado: (2019) -
Fluid removal tolerance during the de-escalation phase: is preload unresponsiveness the best guiding candidate?
por: Ruste, Martin, et al.
Publicado: (2023) -
Escalating burden of SARS-CoV-2 infection in Ethiopia
por: Adane, Kelemework, et al.
Publicado: (2021)